Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 4:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: i-gel Clear all
Completed Phase 1Phase 2 Interventional

Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial

NCT02349009
View directory record Official record
Conditions
Systemic Scleroderma
Interventions
C-82 Topical Gel, 1%, C-82 Topical Gel, Placebo
Drug
Lead sponsor
Prism Pharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Chicago, Illinois • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Sep 25, 2026, 4:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73

NCT01592214
View directory record Official record
Conditions
Staphylococcal Infection
Interventions
Placebo, XF-73 in 2% Klucel gel, XF-73 in 4% Klucel gel
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
2
States / cities
Anaheim, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2016 · Synced Sep 25, 2026, 4:33 PM EDT
Completed No phase listed Observational

DNA Analysis of Tumor Tissue Samples From Patients With Human Papilloma Virus-Associated Cancer of the Oropharynx

NCT00897988
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
gene expression analysis, mutation analysis, polyacrylamide gel electrophoresis, polymerase chain reaction, protein expression analysis, reverse transcriptase-polymerase chain reaction, flow cytometry, immunoenzyme technique, immunologic technique, laboratory biomarker analysis, pharmacological study
Genetic · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 25, 2026, 4:33 PM EDT
Completed Phase 3 Interventional Results available

Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms

NCT01376349
View directory record Official record
Conditions
Breast Cancer, Gynecologic Cancer
Interventions
prasterone, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
280
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 185 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Sep 25, 2026, 4:33 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients with Granuloma Annulare

NCT05580042
View directory record Official record
Conditions
Granuloma Annulare
Interventions
AC-1101
Drug
Lead sponsor
TWi Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Sep 25, 2026, 4:33 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Translating Metabolic Responses to Mechanical Insult Into Early Interventions to Prevent PTOA

NCT04589611
View directory record Official record
Conditions
Osteoarthritis, Post-traumatic Osteoarthritis
Interventions
amobarbital/Gel-One (one dose), Placebo (single dose), amobarbital/Gel-One (two doses), Placebo (two doses)
Drug
Lead sponsor
J L Marsh
Other
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 25, 2026, 4:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Trial to Assess the Safety of Tenofovir Gel and Film Formulations: FAME 04

NCT01989663
View directory record Official record
Conditions
HIV
Interventions
1% vaginally applied tenofovir gel, Tenofovir film- 10mg, Tenofovir Film-40 mg, HEC Placebo Gel, Placebo Vaginal Film
Drug · Other
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Sep 25, 2026, 4:33 PM EDT
Completed Not applicable Interventional Results available

AMNIOEXCEL® Plus vs A Marketed Comparator vs SOC in the Management of Diabetic Foot Ulcers

NCT03547635
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
AMNIOEXCEL Plus Amniotic Membrane, A Marketed Comparator, Standard of Care
Other · Device
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
21 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Fresno, California • Los Angeles, California • Gainesville, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2020 · Synced Sep 25, 2026, 4:33 PM EDT
Withdrawn Phase 1 Interventional

Three Dosing Schedules of Oral Rigosertib in MDS Patients

NCT02075034
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
rigosertib
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Sep 25, 2026, 4:33 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate the Safety of BF-200 ALA (Ameluz®) for Photodynamic Therapy (PDT) in the Treatment of Expanded Fields of Actinic Keratosis (AK)

NCT04319159
View directory record Official record
Conditions
Actinic Keratoses
Interventions
BF-200 ALA and red light LED lamp
Combination Product
Lead sponsor
Biofrontera Bioscience GmbH
Industry
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Sep 25, 2026, 4:33 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics of Ingenol Mebutate Gel in Actinic Keratosis Under Maximum Use Conditions

NCT02124239
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Ingenol mebutate
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Sep 25, 2026, 4:33 PM EDT
Completed Phase 2 Interventional Results available

Effect of a Wide Spectrum Nutritional Supplement on Mitochondrial Function in Children With Autism Spectrum Disorder

NCT03835117
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Wide-spectrum nutritional supplement, Placebo
Drug · Other
Lead sponsor
Rossignol Medical Center
Other
Eligibility
2 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 25, 2026, 4:33 PM EDT
Completed Phase 2 Interventional Results available

Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer

NCT02556632
View directory record Official record
Conditions
Breast Carcinoma, Pain, Radiation-Induced Dermatitis, Stage 0 Breast Cancer
Interventions
Curcumin-based Gel, Dermatologic Complications Management, Laboratory Biomarker Analysis, Placebo, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
Gary Morrow
Other
Eligibility
21 Years and older · Female only
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Newark, Delaware • Decatur, Illinois • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 25, 2026, 4:33 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neurobiology of the Scalp in Seborrheic Dermatitis

NCT02349854
View directory record Official record
Conditions
Seborrheic Dermatitis
Interventions
Biopsy
Procedure
Lead sponsor
Boston University
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Sep 25, 2026, 4:33 PM EDT
Completed Phase 3 Interventional Results available

Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer

NCT00516503
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neurotoxicity, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
baclofen/amitriptyline/ketamine gel, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
165
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 104 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Sep 25, 2026, 4:33 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Safety and Acceptability of Tenofovir 1% Gel in Adolescent Females

NCT02245945
View directory record Official record
Conditions
HIV Prevention
Interventions
TFV 1% vaginal gel, HEC Placebo Gel
Drug
Lead sponsor
CONRAD
Other
Eligibility
15 Years to 17 Years · Female only
Healthy volunteers
Accepts healthy volunteers
U.S. locations
2
States / cities
The Bronx, New York • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Sep 25, 2026, 4:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessment of the I-gel and Air-Q Supraglottic Airways as Conduits for Tracheal Intubation in Children

NCT02189590
View directory record Official record
Conditions
Tracheal Intubation in Children
Interventions
i-gel, air-Q
Device
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
1 Month to 6 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 23, 2014 · Synced Sep 25, 2026, 4:33 PM EDT
Completed Not applicable Interventional

Physiological Investigations of Movement Disorders

NCT01019343
View directory record Official record
Conditions
Parkinson's Disease, Tourette's Syndrome, Tic Disorders, Dystonia, Movement Disorders
Interventions
Transcranial Direct Current Stimulation (tDCS), Eye-tracking Device, Pulsed vibrator, Gait Trainer Treadmill (GTT), Standard psychiatric scales SCID-I, YBOCS and SCI-OBS-lifetime and cognitive scales MMSE and MOCA, iMobility, QMAT, Treadmill Test, Arm Intellistretch Device, Transcranial Sonography (TCS), Behavioral tasks, TMS single/paired pulse, MEG, EEG, MRI techniques, Peripheral Nerve Stimulation, EMG, Trancutaneous spinal direct current stimulation (tsDCS)
Procedure · Device · Other + 1 more
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
1,273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 25, 2026, 4:33 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

The Safety and Efficacy of Supraglottic Airway Use in Children

NCT02202174
View directory record Official record
Conditions
Supraglottic Airway Use in Children
Interventions
Supraglottic Airway Device
Device
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
1 Day to 18 Years
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 28, 2015 · Synced Sep 25, 2026, 4:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparison of I-gel to the Laryngeal Mask Airway

NCT00706823
View directory record Official record
Conditions
Endotracheal Intubation, Supraglottic Airway
Interventions
i-gel airway (Intersurgical Ltd., Wokingham, England), Laryngeal Mask Airway-Unique
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2017 · Synced Sep 25, 2026, 4:33 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Intra-anal Oxymetazoline in Healthy Adult Volunteers

NCT03529487
View directory record Official record
Conditions
Fecal Incontinence
Interventions
Oxymetazoline
Drug
Lead sponsor
RDD Pharma Ltd
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Sep 25, 2026, 4:33 PM EDT
Completed No phase listed Observational

An Observational Trial to Assess the Performance of the TEG® 6s Diagnostic System With the Citrated K, KH, RTH, FFH Cartridge

NCT06352125
View directory record Official record
Conditions
Surgery
Interventions
TEG 6s Citrated K, KH, RTH, FFH Cartridge, Clauss Fibrinogen
Diagnostic Test
Lead sponsor
Haemonetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
San Francisco, California • Aurora, Colorado • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2024 · Synced Sep 25, 2026, 4:33 PM EDT
Completed Phase 2 Interventional Results available

The Effect Of NS-0200 and NS-0300 Versus Placebo on Weight In Obesity

NCT03364335
View directory record Official record
Conditions
Obesity
Interventions
Leu Sil 1.0mg, Leu Sil 4.0mg, Leu Met Sil 1.0mg, Leu Met Sil 4.0mg, Placebo
Drug
Lead sponsor
NuSirt Biopharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
15
States / cities
Mobile, Alabama • Montclair, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Sep 25, 2026, 4:33 PM EDT
Withdrawn Not applicable Interventional

StrataXRT for the Prevention and Treatment of Radiation Dermatitis in Breast Cancer or Head and Neck Cancer Patients

NCT05073172
View directory record Official record
Conditions
Breast Carcinoma, Head and Neck Carcinoma, Radiation-Induced Dermatitis
Interventions
Calendula Ointment, Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment, Polyethylene Glycol Hydrogel, Silicone-based Film Forming Topical Gel, Silver Sulfadiazine, Topical Hydrocortisone
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 5, 2024 · Synced Sep 25, 2026, 4:33 PM EDT